CC‐90009 (Table 1) represents a selective GSPT1 degrader derived from a structurally optimized derivative of CC‐885, maintaining the potent anti‐AML activity of CC‐885 and selectively degrading GSPT1 to enhance both target specificity and therapeutic safety.[103] The anti‐AML activity of CC‐90009 was evaluated on samples from 9 AML patients by the PharmaFlow assay. The gene discussed is GSPT1; the disease is acute myeloid leukemia.